Results 21 to 30 of about 96 (70)

The risk of worsening of myasthenia by cardiovascular medication as reflected by reporting frequency

European Journal of Neurology, Volume 28, Issue 9, Page 2965-2970, September 2021., 2021
From counts of adverse drug reaction reports from databases, the reporting odds ratio can be calculated and serve as a surrogate for the risk of myasthenia worsening due to drugs commonly used in cardiovascular diseases. An increased risk of beta‐blockers and calcium antagonists is confirmed with this method.
Peter Trillenberg, Alexander Katalinic, Julia Thern, Tobias Graf   +3 more
wiley   +1 more source

Worsening of myasthenia due to antiepileptic, antipsychotic, antidepressant, and sedative medication: An estimation of risk based on reporting frequency

European Journal of Neurology, Volume 28, Issue 7, Page 2349-2356, July 2021., 2021
Entries in databases of adverse drug reactions can be used to compare the risk of myasthenia worsening due to drugs. We determined a quantitative surrogate (reporting odds ratio [ROR]) for antiepileptic, antidepressant, neuroleptic, and sedative drugs. Although the ROR was increased for some drugs, their ROR was always smaller than for atorvastatin, a ...
Peter Trillenberg, Alexander Katalinic, Klaus Junghanns, Julia Thern   +3 more
wiley   +1 more source

Embracing Uncertainties Over the Evidence of New Oral Antivirals for COVID‐19: Challenges in Pharmacoepidemiologic Research

, 2023
The Journal of Clinical Pharmacology, Volume 63, Issue 5, Page 521-525, May 2023.
Renato Ferreira da Silva, Ana Marta Silva, Manuela Morato, Inês Ribeiro‐Vaz, Jorge Junqueira Polónia   +4 more
wiley   +1 more source

Profiles and influencing factors of pulmonary fibrosis associated with biologic and conventional disease-modifying antirheumatic drugs for autoimmune diseases: a disproportionality study based on FAERS and VigiAccess

Frontiers in Pharmacology
BackgroundPulmonary fibrosis is a severe and potentially fatal adverse event, and its association with disease-modifying antirheumatic drugs (DMARDs) has raised long-standing concerns. However, systematic investigations on this topic are lacking.
Xinyue Zhang, Xinhui Wu, Cheng Luo, Chun Yang, Nan Jia, Jiayi He, Qian Chen, Fei Wang   +7 more
doaj   +1 more source

Pharmacovigilance evaluation of somatrogon-associated adverse events in real-world databases

Endocrine Connections
Background: Somatrogon, a long-acting recombinant human growth hormone, is used in children with growth hormone deficiency. While clinical trials have shown its safety, real-world post-marketing data are limited, and uncommon or delayed adverse events ...
Mengyuan Cai, Qian Guo, Huqiang Dong, Yabo Wang, Zhongyu Han, Ping Xu   +5 more
doaj   +1 more source

Characterization of skin adverse events associated with cetuximab: real-world insights from the two global pharmacovigilance databases of FAERS and VigiAccess

Frontiers in Oncology
BackgroundCetuximab, an IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is widely used in metastatic colorectal cancer and other solid tumors. Cutaneous adverse events (AEs) are among its most frequent toxicities, but real-
Chenwen Li, Yifei Gao, Min Guang, Huajuan Wu, Yunfei Li, Yaqing Lu, Yan Wei, Xueli Li, Li Yang   +8 more
doaj   +1 more source

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 274-285, July 2026.
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Natalia Sauer, Piotr Giedziun, Jacek Calik, Anna Wiela‐Hojeńska   +3 more
wiley   +1 more source

Common osteoporosis drug associated with increased rates of depression and anxiety

Scientific Reports, 2021
Osteoporosis affects over 10 million Americans over 50. Bisphosphonate therapy, mainly alendronate, is amongst the most prescribed treatments for the disease.
Dro Keshishi, Tigran Makunts, Ruben Abagyan   +2 more
doaj   +1 more source

The Role of Pharmacovigilance Database in Identifying Antibiotic Resistance and Inappropriate Use: An Analysis of VigiBase Reports From Lower‐Middle‐Income Countries

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background Digital databases such as pharmacovigilance (PV) databases could provide unique opportunities to monitor trends in suspected antibiotic resistance, ineffectiveness, and misuse, extending beyond their traditional role of tracking adverse drug reactions (ADRs).
Hager Saleh, Joseph Mitchell, Cecilia Stålsby Lundborg, Megha Sharma   +3 more
wiley   +1 more source

Post-marketing safety signals of Wilson’s disease therapies: evidence from FAERS and VigiBase

Orphanet Journal of Rare Diseases
Introduction Wilson’s disease is a rare autosomal copper metabolism recessive disorder that requires lifelong pharmacological treatment. D-penicillamine and trientine are the most commonly used copper chelators.
Hülya Tezel-Yalçın, Nadir Yalçın, Karel Allegaert, Pınar Erkekoğlu   +3 more
doaj   +1 more source